Virax Biolabs Enter Agreements With Three Chinese Distributors For Its ImmuneSelect Research-Use Immune Profiling Products

ImmuneSelect is Virax's commercially available research-use-only ("RUO") immune profiling portfolio and is distinct from ViraxImmune™, the Company's in-development diagnostic platform. The appointments build on initial ImmuneSelect product sales from Virax's existing mainland China operations and complement its previously announced exclusive commercial supply agreement with Fosun Diagnostics across six Southeast Asian markets.

Under the agreements, the distributors will purchase ImmuneSelect products from Virax for resale within their respective authorised markets and customer segments. The distributors will manage local sales, customer engagement and customer training on product use and storage, with Virax providing product supply, documentation and technical support.

The agreements establish non-exclusive distribution channels for specified customer segments across Beijing, Shanghai, Hubei, Jiangsu, Anhui and Shandong. These territories include major Chinese biotechnology centres such as Beijing's Zhongguancun Life Science Park, Shanghai's Zhangjiang Pharma Valley, Suzhou's BioBAY and Wuhan's BioLake. Suzhou Industrial Park reports that BioBAY alone hosts more than 600 biomedical enterprises, illustrating the scale of one of the research markets Virax intends to address.

KEY HIGHLIGHTS:

Three non-exclusive appointments create distribution routes to specified research customers across six mainland Chinese markets, including major biotech centres in Beijing, Shanghai, Suzhou and Wuhan.
AmyJet, which reports more than 200 international life sciences supplier relationships and already offers ELISpot and other immunology research reagents, will target industrial and biotechnology customers in Beijing, Shanghai and Hubei.
Jiangsu Real-Gen, with a regional presence in Suzhou, Nanjing, Hefei and Jinan, will target academic, biopharmaceutical and other research customers in Jiangsu, Anhui and Shandong.
Zhixi adds a targeted Shanghai academic sales channel, supported by the research-reagent trading experience of its common ownership with Shanghai KEL Biotech.
The initial product focus is ELISpot assay plates and antigen-specific peptide pools for infectious disease, vaccine and cellular immunity research.
Local distribution supports commercial expansion while limiting the need to build a larger direct sales organisation.